ライフサイエンスコーパス: mycobacteria

1 4(-)Sca-1(+)CD122(-)) systems in response to mycobacteria.

2 cience Foundation, Swiss National Center for Mycobacteria.

3 n differences in PD associated with all four mycobacteria.

4 ates during persistent infections than other mycobacteria.

5 the lipoprotein LpqN plays a similar role in mycobacteria.

6 ribute to biofilm production in slow-growing mycobacteria.

7 used in all three centres for the growth of Mycobacteria.

8 tive phosphorylation is poorly understood in mycobacteria.

9 in modulating the cell surface properties of mycobacteria.

10 get space for antibiotic drug development in mycobacteria.

11 he infected cells and decreasing survival of mycobacteria.

12 is cytokines and inhibition of intracellular mycobacteria.

13 et of hemerythrin-like proteins exclusive to mycobacteria.

14 critical for non-replicating persistence of mycobacteria.

15 rD are essential transcription regulators in mycobacteria.

16 he mft gene cluster found in many strains of mycobacteria.

17 and RNA polymerase during stress response of mycobacteria.

18 Mycobacteriophage are viruses that infect mycobacteria.

19 severe infections caused by weakly virulent mycobacteria.

20 scherichia coli, Pseudomonas aeruginosa, and mycobacteria.

21 responsible for the synthesis of lipid I in mycobacteria.

22 ly functional for targeted gene knockdown in mycobacteria.

23 nsically disordered protein domain unique to mycobacteria.

24 ights into OM biogenesis and MA transport in mycobacteria.

25 and reduces numbers of viable intracellular mycobacteria.

26 /or premise plumbing as main contributors of mycobacteria.

27 ngium cellulosum that is also active against Mycobacteria.

28 reactivation have not been characterized in mycobacteria.

29 unctions to promote T cell responses against mycobacteria.

30 y macrophages and dendritic cells exposed to mycobacteria.

31 es they play in the biology and pathology of mycobacteria.

32 ificantly up-regulated following exposure to mycobacteria.

33 ication has not been described previously in mycobacteria.

34 s populate the outer cell wall of pathogenic mycobacteria.

35 milarly impairs migration to newly infecting mycobacteria.

36 on respiratory pathogens and nontuberculosis mycobacteria.

37 or non-covalent trehalose mycolates in live mycobacteria.

38 e able to target different subpopulations of mycobacteria.

39 rgement in compromising host defense against mycobacteria.

40 vated ClpP in firmicutes, is not degraded in mycobacteria.

41 s present in a broad range of nontuberculous mycobacteria.

42 pletion in both environmental and pathogenic mycobacteria.

43 rleukin 1 receptor (IL-1R) signaling against mycobacteria.

44 ce expression of stress response proteins in mycobacteria.

45 y can be exploited for killing intracellular mycobacteria.

46 phages and restricts intracellular growth of mycobacteria.

47 Biotin plays an essential role in growth of mycobacteria.

48 y of Hsps and other stress response genes in mycobacteria.

49 Rv2509 was an essential gene in slow-growing mycobacteria.

50 ely probe the role of OG handling systems in mycobacteria.

51 idespread cysteine-responsive attenuation in mycobacteria.

52 specialized siderophore-import machinery in mycobacteria.

53 the essential mannosyltransferase PimA from mycobacteria.

54 of the host immune response and virulence of mycobacteria.

55 nsible for transport of multiple proteins in mycobacteria.

56 this operon in oxidative stress survival in mycobacteria.

57 nderstanding of MmpL3-targeted inhibition in mycobacteria.

58 component system that is highly conserved in mycobacteria.

59 of standard AFB culture for the isolation of mycobacteria (92.2% versus 47.1%; P < 0.0001).

60 ro culture conditions for drug evaluation in mycobacteria, a factor which appeared to be particularly

61 onserved across pathogenic and nonpathogenic mycobacteria, a feature consistent with an important rol

62 r cells expressing DCAR, and delipidation of mycobacteria abolished this activity.

63 r chemistry and the growth of Legionella and mycobacteria across a transect of bench- and pilot-scale

64 Mycobacteria activated reporter cells expressing DCAR, a

65 Here we show that mycobacteria actively create heterogeneity.

66 ecipher the natural resistance mechanisms of mycobacteria against novel compounds isolated by whole-c

67 guanide dihydrochloride (BBD) as potent anti-mycobacteria agent.

68 Comparison to other EHs from mycobacteria allows insight into the active site plastic

69 r gram-negative bacteria, and nontuberculous mycobacteria, although fungi and viruses were occasional

70 llenged with 147 isolates of rapidly growing mycobacteria and 185 isolates belonging to other species

71 is, is essential for Gram-negative bacteria, mycobacteria and apicomplexans(2,3).

72 x (MAC) are characterized as nontuberculosis mycobacteria and are pathogenic mainly in immunocompromi

73 RNA polymerase has evolved independently in mycobacteria and E. coli, with distinctively different s

74 in PI biosynthesis in prokaryotes, unique to mycobacteria and few other bacterial species, is the rea

75 but are highly susceptible to environmental mycobacteria and have autoinflammatory disease presentat

76 ined to the gut can mute T cell responses to mycobacteria and impair control of secondary infections

77 h that MmpL3 is the MA flippase at the IM of mycobacteria and is the molecular target of BM212, a 1,5

78 retion systems are protein export systems in mycobacteria and many Gram-positive bacteria that mediat

79 Total mycobacteria and Mycobacterium avium complex (MAC) were

80 ative of a P450 family widely distributed in mycobacteria and other bacteria.

81 pidomic analysis platform for drug-resistant mycobacteria and provide direct evidence for characteris

82 hosphate-buffered saline or 10(6)M. canettii mycobacteria and sacrificed over a 28-day experiment.

83 n on innate and adaptive immune responses to mycobacteria and susceptibility to tuberculosis.

84 tinct Th1 subset involved in the response to Mycobacteria and the characterization of two types of Th

85 basis of many of the pathogenic features of mycobacteria and the site of susceptibility and resistan

86 eactions due to infection with environmental mycobacteria and/or bacille Calmette-Guerin (BCG) vaccin

87 l epitopes on commensal gut non-tuberculosis mycobacteria, and (5) the prolonged antibiotic treatment

88 e broad spectrum activity against parasites, mycobacteria, and anaerobic Gram-positive and Gram-negat

89 tors associated with rifampicin tolerance in mycobacteria, and may allow correlation of genetic diver

90 th CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.

91 The MAIT cells are activated by mycobacteria, and prior human studies indicate that bloo

92 em are essential for growth and virulence of mycobacteria, and their inhibitors show promise as antib

93 are important elements of innate immunity to mycobacteria, and these features of bdMphi biology would

94 ted abundant inflammatory nodules containing mycobacteria, and these mice developed nonresolving infl

95 Drug-resistant mycobacteria are a rising problem worldwide.

96 Mycobacteria are a wide group of organisms that includes

97 DI-TOF MS to rapidly identify slowly growing mycobacteria are discussed.

98 Mycobacteria are endowed with a highly impermeable mycom

99 The TopoI-CTDs in mycobacteria are evolutionarily unrelated in amino acid

100 Although mycobacteria are rod shaped and divide by simple binary

101 pecies of multidrug-resistant nontuberculous mycobacteria, are emerging as an important global threat

102 erial P450s, particularly P450s belonging to mycobacteria, are highly conserved both at protein and D

103 ion systems (T7SSs), originally described in mycobacteria, are now known to be widespread across dive

104 hlight RnhC, the sole RNase H1 in pathogenic mycobacteria, as a candidate drug discovery target for t

105 ay also represent a selective drug target in mycobacteria because of the crucial role of these enzyme

106 cts chromosome architecture and of Lsr2 from Mycobacteria, binds A+T-rich sequences throughout the ge

107 ranslational modification that is present in mycobacteria but absent in Escherichia coli, is required

108 gates in eukaryotic cells and potentially in mycobacteria, but the synthesis of enantiomerically pure

109 rtance is bedaquiline (Sirturo), which kills mycobacteria by inhibiting the F(1)F(0) ATP synthase.

110 Mycobacteria cause major diseases including human tuberc

111 ines against TB or in vitro stimulation with mycobacteria (Clinical trial registration: NCT01119521).

112 Mycobacteria concentrations in drinking water did not di

113 Mycobacteria contain multiple Prim-Pols required for les

114 is unclear whether antibiotics penetrate all mycobacteria-containing compartments in the cell.

115 We show that this receptor is acquired by mycobacteria-containing phagosomes via interactions with

116 a pathway required for optimal intracellular mycobacteria control and lung inflammation in vivo.

117 This increased susceptibility to mycobacteria correlated with reduced IFN-gamma/TNF-alpha

118 ast and 96-well-adapted extraction protocol, mycobacteria could be inactivated and extracted for MALD

119 In fact, mycobacteria create variability each time a cell divides

120 Similar to other prokaryotes, mycobacteria decorate their major cell envelope glycans

121 sensitive method for the rapid detection of mycobacteria directly from clinical specimens.

122 on (99 degrees C/30 min), and enrichment for mycobacteria DNA were achieved using an equal volume of

123 Initial validation experiments employed mycobacteria DNA, either extracted or intracellular.

124 Human DNA degraded faster than mycobacteria DNA, resulting in target enrichment.

125 lieved that slow-growing bacteria (including mycobacteria) do not reinitiate chromosome replication u

126 ebrafish-Mycobacterium marinum model to show mycobacteria drive host hemostasis through the formation

127 SMP accumulated in macrophages infected with mycobacteria efficiently killing the infected cells and

128 Mycobacteria elongate and divide asymmetrically, giving

129 TB drug, the development of gene transfer in mycobacteria enabled the discovery of the genes encoding

130 ly incorporate into the mycomembrane in live mycobacteria, enabling in vivo photo-cross-linking and c

131 Our results show that mycobacteria encode a non-conserved protein that control

132 lethality is not understood, in part because mycobacteria encode four MutT enzymes and two MutMs, sug

133 partly due to the special growth states that mycobacteria enter to avoid being killed by antibiotics

134 Our work suggests that if pathogenic mycobacteria fail to prevent lysosomal trafficking, they

135 es a robust competition between the host and mycobacteria for iron acquisition during mycobacterial i

136 vocated for the isolation of rapidly growing mycobacteria from the sputa of cystic fibrosis (CF) pati

137 medium) for the isolation of rapidly growing mycobacteria from the sputum of cystic fibrosis patients

138 agars, for the isolation of rapidly growing mycobacteria from the sputum of patients with CF.

139 susceptibility results of Xpert MTB/RIF and mycobacteria growth indicator tube (MGIT) were confirmed

140 ellet in 2 mL of CSF, and tested 0.5 mL with mycobacteria growth indicator tube culture, 1 mL with Xp

141 Mycobacteria harbor a unique class of adenylyl cyclases

142 pproach adopted to impair iron metabolism in mycobacteria has also been included in this Perspective.

143 Mycobacteria have a complex cell wall structure that inc

144 Mycobacteria have a distinctive glycolipid-rich outer me

145 However, viable mycobacteria have been observed in phagolysosomes during

146 uring infection of cultured macrophages, and mycobacteria have the virulence determinant MarP, which

147 otein that is dispensable for normal growth, mycobacteria have two ClpPs, ClpP1 and ClpP2, which are

148 This suggests that mycobacteria hijacks NQO1 to down-regulate pro-inflammat

149 ed for the differentiation of six species of mycobacteria, i.e., both Mycobacterium tuberculosis comp

150 reports of trade-offs between Legionella and mycobacteria if chloramines are applied as secondary dis

151 It is essential in Mab and other mycobacteria, improving reading frame maintenance on the

152 CF supplementation allowed for detection of mycobacteria in 34 patients with no culturable bacteria

153 rculosis and infections with non-tuberculous mycobacteria in human populations, but the mechanisms by

154 F MS was effective for the identification of mycobacteria in RGM medium.

155 ex (83%) were the most common nontuberculous mycobacteria in Thailand and the United States, respecti

156 re the most commonly isolated nontuberculous mycobacteria in Thailand and the US, respectively.

157 3 sources of data: the reference center for mycobacteria in the Biology Department at Percy Military

158 In contrast, there were various novel mycobacteria in the no-residual DWDS.

159 mmune response towards the killing effect of mycobacteria in the presence of the antibiotics isoniazi

160 e of clinically and environmentally relevant mycobacteria in treated municipal wastewater, suggesting

161 ion of clofazimine (CFZ), enhance killing of mycobacteria in vitro and in infected zebrafish, support

162 s relapse have different immune responses to mycobacteria in vitro than patients who remain cured for

163 Mycobacteria, including the human pathogen Mycobacterium

164 ive elucidation of the mechanisms underlying mycobacteria-induced anemia has important implications f

165 ion in mice to investigate the mechanisms of mycobacteria-induced anemia.

166 nowledge, has not previously been applied in mycobacteria-infected animals.

167 class II-restricted antigen presentation by mycobacteria-infected dendritic cells, we identified the

168 tetramer staining and ex vivo analysis with mycobacteria-infected MR1-deficient cells to demonstrate

169 to Parkinson's disease, Crohn's disease, and mycobacteria infection.

170 hogenetic event in tuberculosis by releasing mycobacteria into the growth-permissive extracellular en

171 Galactan biosynthesis in mycobacteria involves two glycosyltransferases, GlfT1 an

172 ycophospholipid found on the cell surface of mycobacteria, involves the virulence and survival in hos

173 Malawi where sensitization to environmental mycobacteria is common and almost all children are BCG-v

174 The interaction of host cells with mycobacteria is complex and can lead to multiple outcome

175 The biology of mycobacteria is dominated by a complex cell envelope of

176 us etiology (primarily bacteria, followed by mycobacteria) is usually found, noninfectious diseases,

177 independently associated with nontuberculous mycobacteria isolation.

178 ise process regulating biofilm production in mycobacteria, it was shown elsewhere that lsr2 participa

179 Zinc starvation in mycobacteria leads to remodeling of ribosomes, in which

180 regulation have been extensively analysed in mycobacteria, little is known about mechanisms that shap

181 Killed mycobacteria maintained differential hydrophobicity but

182 and cell division are temporally resolved in mycobacteria, making these slow-growing organisms a pote

183 alone (including yeast), and 0.6% contained mycobacteria/molds.

184 ng that to establish a successful infection, mycobacteria must escape out of the initially infected r

185 embers of the order Corynebacterineae (e.g., mycobacteria, nocardia, and rhodococci) share a glycolip

186 ly attempted on presumptive non-tuberculosis mycobacteria (NTM) and the results were initially compar

187 Nontuberculous mycobacteria (NTM) are an important cause of pulmonary d

188 Nontuberculous mycobacteria (NTM) are frequently found in chloraminated

189 Nontuberculous mycobacteria (NTM) are ubiquitous in the environment and

190 Nontuberculous mycobacteria (NTM) commonly colonize municipal water sup

191 strains, and some species of nontuberculous mycobacteria (NTM) compared with that of linezolid.

192 global incidence of the human nontuberculous mycobacteria (NTM) disease is rapidly increasing.

193 robial treatment regimens for nontuberculous mycobacteria (NTM) disease.

194 e method for the isolation of nontuberculous mycobacteria (NTM) from patients with CF.

195 Isolation of nontuberculous mycobacteria (NTM) from the sputum of patients with cyst

196 Nontuberculous mycobacteria (NTM) infect children with increasing frequ

197 Nontuberculous mycobacteria (NTM) infection has attracted increasing at

198 nt tuberculosis (MDR-TB) and non-tuberculous mycobacteria (NTM) infection, which can be used in early

199 Pulmonary disease (PD) due to nontuberculous mycobacteria (NTM) is increasing globally, but specific

200 Infection with nontuberculous mycobacteria (NTM) is of growing clinical concern in peo

201 complex (MABSC) is a form of Nontuberculous mycobacteria (NTM) of special, international concern in

202 Nontuberculous mycobacteria (NTM) represent over 190 species and subspe

203 The prevalence of nontuberculous mycobacteria (NTM) showed a decreasing trend (P = .0032)

204 he frequency of isolation of non-tuberculous mycobacteria (NTM) species from respiratory specimens is

205 ans are regularly exposed to non-tuberculous mycobacteria (NTM) that live in soil and water reservoir

206 76 (75%) of the rapid growing nontuberculous mycobacteria (NTM), and 42/48 (85%) slow growing NTM tes

207 ther method; Legionella spp., nontuberculous mycobacteria (NTM), and Mycobacterium avium complex (MAC

208 ary infection via aerosolized nontuberculous mycobacteria (NTM), it is important to characterize thei

209 nvironmental species known as nontuberculous mycobacteria (NTM), some of which-namely Mycobacterium a

210 uberculosis complex (MTC) and nontuberculous mycobacteria (NTM), using surface-enhanced Raman spectro

211 philum is a rare and emerging nontuberculous mycobacteria (NTM).

212 LAM from MTB and slow-growing nontuberculous mycobacteria (NTM).

213 agar for the isolation of all nontuberculous mycobacteria (NTM).

214 pert MTB/RIF in patients with nontuberculous mycobacteria, old PTB scar, and immune reconstitution sy

215 an that of BCSA (35.7%) for the isolation of mycobacteria (P < 0.0001).

216 Uniquely in mycobacteria, ParA interacts with a polar protein DivIVA

217 We recently showed that in mycobacteria, phenotypically-resistant subpopulations ca

218 In mycobacteria, phosphatidylinositol (PI) acts as a common

219 MTBDRplus was performed on mycobacteria-positive cultures to ascertain acquired dru

220 Mycobacteria possess a multi-layered cell wall that requ

221 Mycobacteria possess a wide range of regulatory proteins

222 Mycobacteria possess the highest P450 diversity percenta

223 eveloped a 3-D system incorporating virulent mycobacteria, primary human blood mononuclear cells and

224 In many bacteria, including mycobacteria, protein aggregates are located at the cell

225 with two media designed for the isolation of mycobacteria (rapidly growing mycobacteria [RGM] medium

226 thy adults who received BCG at birth, 53% of mycobacteria-reactive-activated CD8 T cells expressed CD

227 e a critical first step in understanding how mycobacteria recycle their peptidoglycan.

228 In evolving from ancestral mycobacteria, related to "M. canettii" and M. kansasii,

229 Immediately following infection, mycobacteria rely on PDIM to evade Myd88-dependent recru

230 In addition, we uncover that mycobacteria resist antibiotic lethality through nucleot

231 um kansasii is a slow-growing nontuberculous mycobacteria responsible for coinfections particularly i

232 tive against the persistent, non-replicating mycobacteria responsible for the protracted therapy requ

233 Importantly, metabolome profiling in mycobacteria reveals a significant increase in the level

234 A new selective medium for rapidly growing mycobacteria (RGM medium) was evaluated on respiratory s

235 e isolation of mycobacteria (rapidly growing mycobacteria [RGM] medium and Middlebrook 7H11 agar), fo

236 The mycobacteria RNA polymerase (RNAP) is a target for antim

237 The clade-specific features of the mycobacteria RNAP provide clues to the profound instabil

238 provide clues to the profound instability of mycobacteria RPo compared with E. coli.

239 y testing of 170 isolates of rapidly growing mycobacteria showed equivalent or lower (1- to 8-fold) M

240 imple method for the rapid identification of Mycobacteria species by MALDI-TOF (Matrix-Assisted Laser

241 Interestingly, the transfer of mycobacteria-specific (P25 CD4(+) TCR transgenic) wild-t

242 ycobacterial immunity resulting in decreased mycobacteria-specific and nonspecific immune responsiven

243 assess lung involvement and the frequency of mycobacteria-specific CD4 T-cells.

244 ation of a previously unrecognized subset of mycobacteria-specific CD4(+) T cells that is characteriz

245 was found to dampen IFN-gamma production by mycobacteria-specific CD4(+) T cells.

246 The proportion of mycobacteria-specific CD4+ T cells secreting tumor necro

247 Herein, we describe mycobacteria-specific chemical reporters that can select

248 determine whether BCG vaccination activated mycobacteria-specific MAIT cell responses in humans.

249 Novel strategies for induction of mycobacteria-specific resident memory T cells in the lun

250 93% (95% CI 90-96; 322 of 345 specimens; 356 mycobacteria specimens submitted) accuracy and drug susc

251 Mycobacteria spp., however, are well known for their num

252 Upon contact with mycobacteria, SPPL2a(-/-) bone marrow-derived DCs show e

253 lts show that the suites of VOCs produced by Mycobacteria ssp. change over time and that individual s

254 es, it has long been thought that pathogenic mycobacteria such as Mycobacterium tuberculosis do not r

255 Pathogenic mycobacteria, such as Mycobacterium tuberculosis and Myc

256 Host infection by pathogenic mycobacteria, such as Mycobacterium tuberculosis, is fac

257 phages phagocytosed and eradicated infecting mycobacteria, suggesting that to establish a successful

258 Mycobacteria survive in macrophages despite triggering p

259 eir formidable resistance to antimicrobials, mycobacteria synthesize rare intracellular polymethylate

260 Mycobacteria synthesize the dominant capsule component,

261 mbers of this multigene family occur only in mycobacteria that cause disease.

262 specific phenolic glycolipids (PGLs) in the mycobacteria that cause tuberculosis or leprosy.

263 pecies of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to ind

264 hanges in the genus Mycobacterium Only those mycobacteria that have been isolated from human specimen

265 For tuberculosis-causing mycobacteria, the impact of HGT in the emergence and dis

266 Given the physical asymmetry of mycobacteria, the models that describe coordination of c

267 blishment of an effective immune response to mycobacteria, the possible function of the adaptor molec

268 nobacteria, including the streptomycetes and mycobacteria, the rapid resuscitation from a dormant sta

269 However, in mycobacteria, the role of these systems in genomic integ

270 of glycolipid production are conserved among mycobacteria, these findings obtained with PE from M. sm

271 xtracellular SODs in specific bacteria (i.e. Mycobacteria), throughout the fungal kingdom, and in the

272 the whole-cell drug efflux pump activity of mycobacteria, thus turning out to be promising multidrug

273 sibly increasing the ability of slow-growing mycobacteria to adapt to environmental conditions.

274 bes some of the unique strategies evolved by mycobacteria to import nutrients and other products thro

275 re used by both environmental and pathogenic mycobacteria to secrete proteins across their complex ce

276 The mycolic acid-containing cord factor of mycobacteria, trehalose dimycolate, activates the C-type

277 Pathogenic mycobacteria trigger formation of organized granulomas.

278 In Mycobacteria tuberculosis and Francisella tularensis, bi

279 We have previously demonstrated that Mycobacteria tuberculosis chaperonin 60.1 inhibits leuco

280 scherichia coli, Listeria monocytogenes, and Mycobacteria tuberculosis.

281 In mycobacteria, type VII secretion systems (T7SSs) are ded

282 Mycobacteria use type VII secretion systems to secrete p

283 gger signalling through direct engagement of mycobacteria using tranfectant cells incorporating a rep

284 ggesting that these proteins are involved in mycobacteria virulence.

285 Hospital, identification of any presumptive mycobacteria was attempted and compared with the results

286 rial activity of Pep-H against intracellular mycobacteria was enhanced in both the nanoformulations a

287 ll-cycle-dependent gene regulation occurs in mycobacteria, we characterized the temporal changes in t

288 To understand biotin biosynthesis in mycobacteria, we executed a genetic screen in Mycobacter

289 Mycobacteria were detected in 24 samples (86%) using the

290 Viable mycobacteria were immobilized, and single organisms were

291 Mycobacteria were isolated from 28 patients (prevalence,

292 By using a combination of all methods, 98 mycobacteria were isolated from 869 samples (11.3%).

293 Nontuberculous mycobacteria were isolated in 46 children (10.8%); 45.7%

294 his behaviour can be extended to saprophytic mycobacteria, whose more complex genomes encode more Mce

295 Finally, we discovered that treatment of mycobacteria with ethambutol, a front-line tuberculosis

296 omplex, multitiered system of OG handling in mycobacteria with roles in oxidative stress resistance,

297 viability and in interactions of pathogenic mycobacteria with their hosts.

298 et of hemerythrin-like proteins exclusive to mycobacteria, with likely roles in protection against ho

299 cell lipid droplets, but heterogeneously in mycobacteria within a variety of intracellular compartme

300 locally and at the Swiss National Center for Mycobacteria, Zurich, Switzerland.